首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1071篇
  免费   39篇
管理学   97篇
民族学   6篇
人口学   90篇
丛书文集   8篇
理论方法论   138篇
综合类   4篇
社会学   679篇
统计学   88篇
  2023年   9篇
  2022年   3篇
  2021年   7篇
  2020年   20篇
  2019年   35篇
  2018年   21篇
  2017年   54篇
  2016年   21篇
  2015年   26篇
  2014年   26篇
  2013年   212篇
  2012年   36篇
  2011年   32篇
  2010年   28篇
  2009年   31篇
  2008年   38篇
  2007年   36篇
  2006年   32篇
  2005年   29篇
  2004年   21篇
  2003年   26篇
  2002年   29篇
  2001年   25篇
  2000年   25篇
  1999年   25篇
  1998年   25篇
  1997年   17篇
  1996年   23篇
  1995年   18篇
  1994年   19篇
  1993年   13篇
  1992年   20篇
  1991年   6篇
  1990年   10篇
  1988年   8篇
  1987年   5篇
  1986年   8篇
  1985年   10篇
  1984年   12篇
  1983年   7篇
  1982年   9篇
  1981年   11篇
  1980年   7篇
  1979年   5篇
  1978年   3篇
  1976年   3篇
  1975年   4篇
  1972年   3篇
  1968年   2篇
  1967年   2篇
排序方式: 共有1110条查询结果,搜索用时 125 毫秒
1.
ABSTRACT

The cost and time of pharmaceutical drug development continue to grow at rates that many say are unsustainable. These trends have enormous impact on what treatments get to patients, when they get them and how they are used. The statistical framework for supporting decisions in regulated clinical development of new medicines has followed a traditional path of frequentist methodology. Trials using hypothesis tests of “no treatment effect” are done routinely, and the p-value < 0.05 is often the determinant of what constitutes a “successful” trial. Many drugs fail in clinical development, adding to the cost of new medicines, and some evidence points blame at the deficiencies of the frequentist paradigm. An unknown number effective medicines may have been abandoned because trials were declared “unsuccessful” due to a p-value exceeding 0.05. Recently, the Bayesian paradigm has shown utility in the clinical drug development process for its probability-based inference. We argue for a Bayesian approach that employs data from other trials as a “prior” for Phase 3 trials so that synthesized evidence across trials can be utilized to compute probability statements that are valuable for understanding the magnitude of treatment effect. Such a Bayesian paradigm provides a promising framework for improving statistical inference and regulatory decision making.  相似文献   
2.
3.
4.
5.
Colorism is a persistent problem for people of color in the USA. Colorism, or skin color stratification, is a process that privileges light-skinned people of color over dark in areas such as income, education, housing, and the marriage market. This essay describes the experiences of African Americans, Latinos, and Asian Americans with regard to skin color. Research demonstrates that light-skinned people have clear advantages in these areas, even when controlling for other background variables. However, dark-skinned people of color are typically regarded as more ethnically authentic or legitimate than light-skinned people. Colorism is directly related to the larger system of racism in the USA and around the world. The color complex is also exported around the globe, in part through US media images, and helps to sustain the multibillion-dollar skin bleaching and cosmetic surgery industries.  相似文献   
6.
We propose methods for monitoring the residuals of a fitted ARIMA or an autoregressive fractionally integrated moving average (ARFIMA) model in order to detect changes of the parameters in that model. We extend the procedures of Box & Ramirez (1992) and Ramirez (1992) and allow the differencing parameter, d to be fractional or integer. Test statistics are approximated by Wiener processes. We carry out simulations and also apply our method to several real time series. The results show that our method is effective for monitoring all parameters in ARFIMA models.  相似文献   
7.
8.
9.
10.
Summary.  In studies to assess the accuracy of a screening test, often definitive disease assessment is too invasive or expensive to be ascertained on all the study subjects. Although it may be more ethical or cost effective to ascertain the true disease status with a higher rate in study subjects where the screening test or additional information is suggestive of disease, estimates of accuracy can be biased in a study with such a design. This bias is known as verification bias. Verification bias correction methods that accommodate screening tests with binary or ordinal responses have been developed; however, no verification bias correction methods exist for tests with continuous results. We propose and compare imputation and reweighting bias-corrected estimators of true and false positive rates, receiver operating characteristic curves and area under the receiver operating characteristic curve for continuous tests. Distribution theory and simulation studies are used to compare the proposed estimators with respect to bias, relative efficiency and robustness to model misspecification. The bias correction estimators proposed are applied to data from a study of screening tests for neonatal hearing loss.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号